PMDA drug package insert
ホスリボン配合顆粒
PMDA Prescription drug · ゼリア新薬工業株式会社 · package insert Jul 3, 2023
Key facts
| Brand names | ホスリボン配合顆粒 |
|---|---|
| Nonproprietary names | リン酸二水素ナトリウム一水和物・無水リン酸水素二ナトリウム |
| Companies | 製造販売元／ゼリア新薬工業株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 経口リン酸製剤 |
| Therapeutic category codes | 87322 |
| YJ codes | 3229103D1020 |
| Approval numbers | 22400AMX01502000 |
| Package insert edition | 第1版 |
| Package insert date | Jul 3, 2023 |
| PMDA document key | 380077_3229103D1020_1 |
| PMDA company code | 380077 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: